| Cover | Mar. 25, 2021 |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Mar. 25, 2021 |
| Entity File Number | 001-37719 |
| Entity Registrant Name | Corvus Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001626971 |
| Entity Tax Identification Number | 46-4670809 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 863 Mitten Road, Suite 102 |
| Entity Address, City or Town | Burlingame |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94010 |
| City Area Code | 650 |
| Local Phone Number | 900-4520 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, Par Value $0.0001 per share |
| Trading Symbol | CRVS |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | true |
